Joining the dots: Answers
- PMID: 35084566
- DOI: 10.1007/s00467-021-05415-y
Joining the dots: Answers
Keywords: Acute kidney injury; Acute liver failure; Deferasirox; Iron chelation therapy; Pharmacogenomics; Renal tubular acidosis.
References
-
- Fucile C, Mattioli F, Marini V, Gregori M, Sonzogni A, Martelli A, Maximova N (2018) What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosis. Ther Clin Risk Manag 14:1649–1655. https://doi.org/10.2147/TCRM.S170761 - DOI - PubMed - PMC
-
- Rodríguez-Soriano J, Vallo A (1990) Renal tubular acidosis. Pediatr Nephrol 4:268–275. https://doi.org/10.1007/BF00857675 - DOI - PubMed
-
- Papadopoulos N, Vasiliki A, Aloizos G, Tapinis P, Kikilas A (2010) Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major. Ann Pharmacother 44:219–221. https://doi.org/10.1345/aph.1M440 - DOI - PubMed
-
- Sakurai A, Tamura A, Onishi Y, Ishikawa T (2005) Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications. Expert Opin Pharmacother 6:2455–2473. https://doi.org/10.1517/14656566.6.14.2455 - DOI - PubMed
-
- Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Jang IJ, Lee DH, Lee JS (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24:2237–2244. https://doi.org/10.1200/JCO.2005.03.0239 - DOI - PubMed
LinkOut - more resources
Full Text Sources
